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Introduction
Oncogene-bearing transgenic and tumor suppressor 'knock out' mice are invaluable tools for the evaluation of the molecular steps leading to the establishment of a fully malignant phenotype. [1] [2] [3] In previous articles we suggested that these mice can also be exploited for testing novel therapeutic strategies, including gene therapy approaches. [4] [5] [6] [7] Among the advantages of using transgenic mice to evaluate tumor growth inhibition, is the fact that at least one step leading to cell transformation is exactly defined. Therefore, the effect of targeting a specific oncogene by traditional or novel means, such as antisense methods, or of restoring the tumor suppressor function by gene transfer, can be accurately evaluated by choosing the appropriately modified animals.
So far, most of the cancer gene therapy studies have used transplantable tumor cell lines which are injected into syngenic hosts or immunodepressed animals. Although this procedure can be easily implemented and solves some practical problems such as homogeneity and easy availability of tumor cells, it is not known to what extent the results obtained with these neoplasias are representative of the human situation. In humans, most solid tumors grow slowly and progressively, acquiring the capacity of adapting to the microenvironment and escaping the host immune system.
We have previously described a transgenic mouse lineage overexpressing the activated rat neu oncogene in the mammary gland under the control of the mouse mammary tumor virus long terminal repeat (MMTV-LTR). These mice develop breast tumors which present several features in common with human mammary tumors, including the ability to metastasize to distant organs. 6, 8 In addition, these tumors arise with high reproducibility in 100% of the females within the first 3 months, allowing easy assessment of the effects of any novel therapeutic approach. 4, 5 We and others have previously used these mice to test two widely used approaches of cancer gene therapy, based on suicide gene transfer or antisense-mediated oncogene inhibition. [4] [5] [6] 9 Taken together, these studies demonstrated that, while complete eradication has been reported in animal models based on transplantable tumors, only partial growth inhibition has been obtained in MMTV-neu mammary tumors. This implies that these neoplasias are more difficult to eradicate than transplantable tumors. However, better results could be achieved by combining approaches based on different mechanisms, as suggested by recent studies on transplantable tumors. [10] [11] [12] Immune system manipulation is a different gene therapy approach that has been investigated by many authors. IL-4 is a potent cytokine which is able to induce a strong antitumor response, partially dependent on T lymphocytes and macrophages and granulocytes. 13 The activation of the lymphoid component seems to be necessary in order to activate a long-term antitumor effect. In addition, IL-4 has been reported to have a direct antiproliferative effect on several tumor cell lines, [14] [15] [16] although in other studies, only the estrogen-induced and not the basal growth of breast cancer cells seems to be affected by IL-4. [17] [18] [19] In the present study, we evaluated the systemic and local effects of in vivo IL-4 gene transfer in our MMTVneu model. The results suggest that IL-4 could be usefully added to other approaches in a combined strategy against breast tumors.
Results
IL-4 exerts an inhibitory effect on breast tumor growth locally Right side tumors of MMTV-neu transgenic female mice were inoculated with retrovirus producer cells (RPC) bearing the IL-4 gene (E86.L4SN) or the HSVtk gene (SBA), as a control to assess nonspecific effects due to the presence of a retroviral vector, or with PBS. The contralateral side tumors were not injected. We have previously demonstrated that the relative ratio of the weight of the tumors of the two sides is a measure of the inhibitory effect of the putative antitumoral agent at the local level. [4] [5] [6] The transduction of the tumor masses with the IL-4 gene was demonstrated by PCR on DNAs extracted from tumors analyzed 4 and 14 days after treatment (data not shown). In addition, we performed IL-4 dosages by an ELISA test in extracts from breast tumors taken at 4 (when packaging cells are still alive), 30 and 90 days after inoculation of packaging cells. While tumors from control mice had a mean IL-4 level of 5.1 ± 1.5 pg/mg of proteins, the injected tumors showed a mean of 203 ± 33, 5 ± 27 and 14 ± 2 pg/mg of proteins at the three time-points, and uninjected tumors in IL-4-treated mice had levels of 32 ± 7.7, 3.5 ± 1.3 and 3.3 ± 1. This suggests that IL-4 is produced in vivo at the beginning of the treatment, but that it declines over time, being still significant at 30 days, and reaching levels similar to those of control mice after 3 months.
In a first set of experiments, 3-month-old mice were treated with a single injection of packaging cells carrying either the IL-4 or the HSVtk genes. At this age, tumors have a size of about 4 mm, representing about 100 mg of weight for each tumor. The effect on the local tumor growth was evaluated after 1 (group A, 40 tumors) or 2 months (group B, 18 tumors) ( Table 1 ). The ratio between untreated and IL-4-treated tumors was 1.53 and 1.65 respectively, in both groups reaching a high statistical significance in comparison with untreated and HSVtkinjected mice (P Ͻ 0.001 CTR). This suggests that IL-4 treatment exerts an inhibitory effect locally. No statistically significant difference was observed between untreated and HSVtk-injected mice, in which the ratio was about 1.0 (as expected, since no ganciclovir was administered).
In another experiment, 45-day-old female mice were injected in the mammary gland in the nipple area with E86.L4SN, SBA cells or PBS as previously described and killed when at least one of the tumors reached the size of approximately 1 cm of maximal diameter (Table 1 , group C). While at least one tumor from all untreated and SBA-treated mice reached this size within 4 months, IL-4-inoculated mice took 120-180 days to reach this endpoint ( Figure 1 ). While in this protocol the difference between SBA-injected and PBS-treated mice was barely significant (P = 0.0490, logrank test), indicating the presence of nonspecific effects of in vivo transduction, the survival of IL-4-treated mice was far more significant compared with that of PBS-treated animals (P = 0.0029). Furthermore, the ratio between the size of untreated and treated tumors in IL-4-injected mice was 2.16 (P Ͻ 0.001 versus PBS and SBA-treated mice, Table 1 ), in keeping with the findings in groups A and B. There was no difference between the number of breast tumors in treated and untreated mice, but when the total weight of tumors of treated mice was compared with the weight of tumors in the control, the difference was highly significant (5.51 ± 0.57 g in treated mice versus 9.70 ± 1.14 g in controls, P Ͻ 0.02), in spite of the fact that Il-4-treated mice were killed at an older age than control mice, as shown in Figure 1 . We also verified, by in vitro experiments, that IL-4 does not have a direct inhibitory effect on the growth of MMTV-neu mammary tumor cells. We found by RT-PCR that an established cell line from a MMTV-neu transgenic mice (MG1361) expresses the IL-4 receptor, but its proliferation rate is not affected by increasing concentrations of recombinant murine IL-4 (0.1-50 ng/ml, data not shown). 
IL-4 exerts a systemic antitumor effect
We also evaluated whether IL-4 could act at the systemic level. This putative systemic action was investigated by comparing the total weight of tumors of the untreated side in IL-4 or SBA-treated mice (19 and 11 mice, respectively) with that of tumors arising in transgenic mice treated with PBS alone (11 mice). Statistical analysis revealed a highly significant difference between the IL-4 and the PBS control group (P Ͻ 0.005, Table 2 ), suggesting that this IL-4 treatment protocol also has a systemic effect on tumor growth.
Histopathological analysis
All IL-4-injected, SBA-injected and untreated tumors were subjected to histopathological analysis, together with other tissues coming from the same animals (liver, kidney, lung, spleen). Apart from the size of the tumors no difference was found in the tumor structure of the three groups of mice. Histologically, the mammary tumors were carcinomas characterized by large solid lobules of undifferentiated cells. Most of the solid masses of tumor cells displayed some evidence of tubular morphology. Lobules were often separated from one another by thin trabeculae of fibrous tissue. Occasionally, the largest solid areas of tumor became necrotic. Mitotic figures were often seen. Between and around neoplastic lobules, an interstitial inflammatory infiltrate characterized by the presence of macrophages was often seen in both IL-4-and SBAtreated tumors (Figure 2 ), but only tumors from IL-4-treated mice showed a large number of eosinophils (see Figure 2A ).
Discussion
The need to integrate different strategies for the cure of human tumors has long been recognized, leading to combined approaches based on surgery, radiotherapy and chemotherapy. Gene therapy-based strategies can be an additional tool in the attempt to eradicate established neoplasias. So far, in spite of some promising results obtained in animal models, gene therapy alone has failed in human protocols aimed at the complete eradication of neoplasias. However, integrated strategies comprising various gene transfer-based approaches can be devised and used with traditional means such as chemo-or radiotherapy. 20 In this article we have demonstrated that the IL-4 gene introduced locally in spontaneously growing breast tumors can reduce their growth in a statistically significant manner. As found in previous studies exploiting the same MMTV-neu transgenic model with different therapeutic strategies, no complete regression of However, our partial therapeutic results also reflect the nature of the tumor in our model, since, as previously discussed (see Introduction and Refs 4-6), our system is closer to its human counterpart than other models based on transplantable tumors, although the neu oncogene activation, in contrast to what happens in human breast carcinoma, is present in every mammary cell, giving rise to multicentric primary tumors. The fact that complete eradication in human clinical trials has not been consistently obtained supports our argument that tumors originating in their natural host are more difficult to cure than those artificially transplanted. Since in our model IL-4 does not seem to have a direct antiproliferative effect on tumor cells, it is likely that the local and systemic antitumor effect observed on breast tumors in vivo is due to different, host-mediated mechanisms. Indeed, by acting as an immune system stimulator, IL-4 can induce a local and systemic reaction against tumor cells. [21] [22] [23] The presence of a large number of eosinophils only in the stroma of mammary tumors treated with IL-4 can be explained by the role played by IL-4 in cytokine-mediated regulation of type I hypersensitivity. 13 As no eosinophils were seen in non-injected contralateral tumors in IL-4 treated mice, it is likely that other cellular components of the immune response were instrumental in mediating the partial systemic effect detected in our model. In addition, IL-4 has recently been proposed to have an anti-angiogenic effect, 24 although this activity was not evaluated in our study.
We can conclude that the results obtained with IL-4 gene transfer seem to be promising even though complete eradication of tumors has not yet been achieved. We are now going to verify whether the efficacy of this approach can be improved by other experimental protocols, including repeated intratumoral injections of IL-4 RPC, inoculation of tumors of both sides of the animals or association with other forms of gene therapy.
Materials and methods

Cell lines
The retroviral producer cell (RPC) line PA317.STK.SBA (here defined as SBA), expressing the HSVtk gene, was obtained and characterized as described previously. 25 To prepare E86.L4SN RPC, the murine IL-4 cDNA was cloned in the EcoRI site of a pLXSN plasmid and transfected by lipofection (DOTAP; Roche Diagnostics, Monza, Italy) in GP+E86 ecotropic packaging cells (obtained from Dr A Bank, Columbia University, New York). After G418 selection (0.5 mg/ml of active drug) several clones were isolated and tested for retroviral titer as described previously 25 and for IL-4 production by an ELISA-based assay (Biosource International, Camarillo, CA, USA). Two clones were used in this study: clone 6 has a titer of 3 × For growth rate analysis, 10 4 MG1361 cells 7 were plated in 96-well plates in the presence of different concentrations of recombinant murine IL-4 (0.1-50 ng/ml, Biosource International). Cell proliferation was measured after 24, 48 and 72 h by the WST-1 colorimetric assay (Roche Diagnostics SpA), according to the manufacturer's instructions. Statistical analysis was performed by paired t test.
In vivo treatments
The production and screening of MMTV-neu transgenic mice as well as the histological features of the tumors have been previously described. IL-4 levels were assessed in tumors from control transgenic mice and in tumors inoculated or not with IL-4 producer cells at 4, 30 and 90 days after the treatment. Samples were homogenised in PBS at 4°C for 15 min, centrifuged at 8000 g for 10 min at 4°C and the supernatant was frozen at −80°C until analysis was performed with an ELISA test (Biosource International). The IL-4 level was expressed as pg/mg of total proteins ± s.e.
Mice were subjected to different treatment protocols. Two groups of 3-month-old mice were treated as described and each tumor was removed and weighed 1 (group A) or 2 (group B) months after treatment. In another set of experiments (group C), mice were inoculated at 45 days, before the appearance of clinically detectable tumors (at this age, however, the mammary tumors are already histologically detectable) and compared with untreated mice. Mice were monitored twice a week until the tumors reached the mass of approximately 1 cm of maximal diameter. At that stage they were killed and necropsy was performed essentially as previously described. 6 The local effect of the treatments on tumor growth was expressed as a ratio between the weights of tumors of the left (untreated) and right (treated) side in the same animal. 1, 2, 6 The systemic effect on tumor growth was evaluated by comparing the total weight of the tumors grown in the non-injected (left) side in treated mice with that of control mice (see also Results).
Statistical analysis of the data was carried out by the Bonferroni test.
